Rebound oder nicht?

ih.advfn.com/...a&cb=1221756771&article=28203964&symbol=NY^GNW

Shares of insurer Genworth fall on mortgage worries
Date : 09/18/2008 @ 12:31PM
Source : TFN
Stock : Genworth Financial I (GNW)
Quote : 5.5508  -4.2892 (-43.59%) @ 12:33PM


Shares of insurer Genworth fall on mortgage worries

       NEW YORK, Sept 18 (Reuters) - Shares of Genworth Financial fell 40 percent
on Thursday as investors grew concerned the mortgage insurer could be next to be
hurt by problems in the nation's housing market.
      Genworth shares dropped to $5.83, plunging past a 52-week low.
      "We think the shares are being punished because like AIG, Genworth is an
insurer with above-average exposure to the U.S. housing market," said Merrill
Lynch analyst Edward Spehar in a research note.
      However, Spehar downplayed those concerns, saying Genworth did not have a
liquidity issue, and was not expected to need to raise capital.
      AIG's large mortgage losses left it on the verge of collapse, forcing it
to agree to a $85 billion bailout from the U.S. government on Tuesday.
   (Reporting by Lilla Zuill; Editing by Brian Moss) Keywords: GENWORTH/SHARES    
Please write your own byline and save in your preferences
vj

COPYRIGHT

Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.

I believe many investors are asking themselves why did Genworth's shares drop after getting a buyout offer since a takeover deal would normally send a stock soaring. I think there are a number of reasons for this. I don't think there is anything wrong with this deal as long as it gets regulatory approval. China Oceanwide and its chairman seem to be well financed and savvy buyers of financial assets. I think the announcement of the deal at $5.43 per share "capped" the potential upside for investors, and that was a disappointment for many shareholders. After all, if Genworth was trading at $5.20 per share just before the deal, then it makes sense to sell the stock because the most you might get is another 23 cents or just around 4% upside, and that is only if you patiently wait for months and if the deal goes through. The lack of a real takeover premium also created a situation whereby it made sense for short sellers to step into this stock and that created selling pressure as well.
Most takeover deals offer a significant premium and yet still trade for a discount to the deal price just in case the deal fails to go through. However, in this case, there was really no premium and therefore the market price of Genworth's stock was quickly adjusted downward in order to provide a typical discount in the event a deal does not go through. Here is an example of another deal which has some similarities. In October 2015, Walgreens Boots Alliance (NASDAQ:WBA) announced a deal to buy Rite Aid (NYSE:RAD) for $9 per share. When that news came out, Rite Aid's shares dropped about 8% to just around $7.97 even though the buyout price was significantly higher. Clearly, some investors believed there could be some antitrust or other regulatory issues with this deal and therefore wanted some type of "risk-premium" or discount to be built into the shares in the event the deal was not approved. Now that deal approval appears to be more likely, Rite Aid's shares are trading at about $8.40 per share. I believe the deal to buy Genworth has a strong chance of going through, and that when updates are announced and regulatory hurdles are cleared, the current discount (to the buyout price of $5.43 per share) of about 35% in Genworth shares will shrink.

If the deal goes through, then Genworth's shares could rise by about 35%, but I also believe that if the deal falls through, the shares will rise as well. That is because investors will again have more potential upside if they buy Genworth's shares. Right now, tax loss selling and some uncertainty as to whether the deal will go though are holding the stock back. Here is how I see it. If the deal goes through, that will bring about the certainty of shareholders receiving $5.43 per share in cash, and if the deal collapses, it will create the certainty of knowing Genworth can benefit from rising rates and the stock no longer has a cap on it.
I recently started buying Genworth shares again because at just $4 per share, I see a "win-win" situation for shareholders. If the deal goes through, I will see gains of about 35%, and if it does not go through, I could see even bigger gains especially in the long run, as Genworth appears to have probably better options to create shareholder value. For example, the rising interest rate environment has sent many financial stocks soaring recently, but this deal seems to have capped it for Genworth. Since the election, other mortgage insurance stocks like Radian Group (NYSE:RDN) have surged about 50%, and MGIC's (NYSE:MTG) shares are up about 30%. Based on recent statements from the Federal Reserve, many analysts now believe we could see four rate hikes in 2017 and 3.5% yields on 10-Year Treasury bonds. That rate environment would be hugely beneficial for Genworth, and yet none of this appears to be priced in as it has been left out of the major rally in financial stocks due to the deal capping the upside at $5.43 per share.
Besides the fact that the end of tax loss selling could help push Genworth's shares higher, here are a couple of other positives to consider. Genworth Australia (GMA.AX) and Genworth Canada (MIC.TO) are trading near 52-week highs right now. These are very valuable and liquid assets, and Genworth owns stakes of about 50% in each of these publicly-traded companies. Genworth Australia has a current market cap of about $1.62 billion, and Genworth Canada has a market cap of $3.14 billion. That means Genworth's stakes in these companies are valued at about $2.4 billion, which is actually more than the current market cap of the company itself, which is about $2 billion. That shows a lot of potential value that could eventually be unlocked, especially if GNW succeeds in turning the long-term care division into the consistently profitable business that it once was. Genworth has been asking for and receiving major policy premium increases, and that, combined with mortality rates, should get this division back on track.

According to an RBC Capital Markets analyst, Genworth is a "Trump stock" as it should benefit from lower corporate taxes and rising rates. When searching for "Trump" stocks, the analyst looked for companies with a low price-to-earnings multiple, a domestic orientation, superior operating leverage, high corporate taxes, and greater volatility. The list of "Trump" stocks has 40 small- and mid-cap stocks in it. According to shortsqueeze.com, there are nearly 15 million shares short, and with an average trading volume of about 5 million shares traded daily, this represents about three days worth of trading volume. This is not enough to cause a short squeeze, but it could add to the potential buying pressure in early 2017, as tax loss selling ends and as investors look for solid value in the New Year.
I think Genworth could get more for its shareholders without the deal, but let's assume it goes through, in which case, shareholders get $5.43 per share in cash. This would be a gain of roughly 35%. That is too large of a discount, especially for a stock that could be better off if the deal is not completed. Because of this and the other positive factors surrounding this stock, like rising rates and the potential for significant corporate tax cuts and deregulation by a Trump Administration, I believe the discount to the deal offer of $5.43 per share will narrow significantly. I think the combination of these factors along with the end of tax loss selling and some short covering will push Genworth's shares back above $4.50 in January, which offers investors a potential gain of about 10% in just a short time, and yet, even at about $4.50, still would offer additional upside of more than 20%, if the buyout deal goes through.

Enact's Baa1 IFS rating also reflects the company's solid position in the US mortgage insurance market and good client diversification, and its consistent GSEs' PMIERs sufficiency ratio (approx. 176% at the end of Q1 2022). The firm's conservative investment portfolio, together with underwriting discipline aimed at improved profitability and market presence, and extensive reinsurance program also support the ratings. Moody's expects Enact's leverage ratios to be around 15% in the near term. These strengths are tempered by the commodity-like nature of the mortgage insurance product and the fact that the MI sector's fortunes are greatly influenced by lenders, the GSEs, public policy decisions, and other uncontrollable variables, including competition from government-sponsored mortgage insurers. ...

... The stable outlook [Genworth rating Ba2] reflects the company's good liquidity and the expectation that Genworth Holdings will further increase liquidity with periodic dividends from Enact subject to its board approval and the continued emergence of cash tax payments from its subsidiaries as part of its tax sharing arrangements, albeit, lower over the next few years as compared to 2021. ..."

www.moodys.com/research/...ings-outlook-stable--PR_1000006536

"... Die Heraufstufung der Ratings von Enact spiegelt auch Verbesserungen des gesamten Kreditprofils des Unternehmens wider, einschließlich seiner Marktposition, Rentabilität, Kapitalausstattung und finanziellen Flexibilität. Im ersten Quartal 2022 lag der Marktanteil von Enact am Markt für private Hypothekenversicherungen bei rund 18%, gegenüber 16,6% im Jahr 2021. Enact verzeichnete 2021 einen Nettogewinn von 546,7 Mio. USD und eine kombinierte Schaden-Kosten-Quote von 38 %. Moody's erwartet, dass die Rentabilität von Enact in der zweiten Jahreshälfte 2022 und bis in das Jahr 2023 hinein stark bleiben wird, da steigende Stornoraten und höhere Zinssätze die Einnahmen erhöhen, auch wenn das Volumen der Hypothekendarlehen tendenziell zurückgehen dürfte.

Das Baa1 IFS-Rating von Enact spiegelt auch die solide Position des Unternehmens auf dem US-Hypothekenversicherungsmarkt und die gute Kundendiversifizierung sowie die konsistente PMIERs-Suffizienzquote der GSEs (ca. 176% zum Ende des ersten Quartals 2022) wider. Das konservative Anlageportfolio des Unternehmens, die auf eine verbesserte Rentabilität und Marktpräsenz ausgerichtete Underwriting-Disziplin sowie das umfangreiche Rückversicherungsprogramm stützen ebenfalls die Ratings. Moody's erwartet, dass der Verschuldungsgrad von Enact in naher Zukunft bei etwa 15 % liegen wird.  ...

... Der stabile Ausblick [Genworth-Rating Ba2] spiegelt die gute Liquidität des Unternehmens und die Erwartung wider, dass Genworth Holdings die Liquidität durch regelmäßige Dividenden von Enact vorbehaltlich der Genehmigung durch den Vorstand und die fortgesetzten Steuerzahlungen der Tochtergesellschaften im Rahmen der Steueraufteilung weiter erhöhen wird, wenn auch in den nächsten Jahren niedriger als 2021. ..."

Übersetzt mit deepl.com